Perpetua Medical (PERP) Q4 2025 earnings summary

Executive summary

• Net sales for 2025 reached 14,560 KSEK, up 110% year-over-year, driven by acquisitions and business transformation.

• Operating income for the year was 2,044 KSEK, a turnaround from -2,456 KSEK in 2024.

• Cash flow for the year was -5,067 KSEK, with cash at year-end at 4,333 KSEK.

• Major capital raise of 20 MSEK (18.7 MSEK net) completed in Q4 to fund acquisitions and growth.

• Strategic focus on acquiring and developing profitable healthcare subsidiaries, with ES-Medical and Spirotronic as key assets.

Financial highlights

• Q4 net sales: 5,157 KSEK, up 24% from Q4 2024.

• Q4 operating result: -3,922 KSEK (Q4 2024: -1,105 KSEK), impacted by new subsidiary costs.

• Full-year EPS: 0.26 SEK (2024: -0.56 SEK).

• Equity at year-end: 30,775 KSEK (2024: 10,865 KSEK).

• Soliditet (equity ratio): 49% (2024: 58%).

Outlook and guidance

• Continued focus on acquisition pipeline and integration of subsidiaries.

• Expectation of strong growth in 2026, especially from Spirotronic and ES-Medical.

• Lean parent company structure and disciplined financing for future acquisitions.